Your session is about to expire
← Back to Search
Gene Therapy
Gene Therapy for Leber Congenital Amaurosis
Phase 1 & 2
Recruiting
Research Sponsored by Opus Genetics, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
This trial tests a gene therapy to help people with an inherited eye disorder that causes vision loss.
Who is the study for?
Adults with inherited retinal degeneration due to LCA5 gene mutations, who have visual acuity less than 20/80 and detectable photoreceptors. Candidates must be able to undergo surgery, follow post-surgery instructions, use effective contraception if of childbearing potential, and commit to the study protocol.Check my eligibility
What is being tested?
The trial is testing a subretinal gene therapy called OPGx-001 for safety and initial effectiveness in treating vision loss caused by LCA5-associated retinal degeneration. It involves surgical delivery of the AAV8.hLCA5 gene therapy directly into the retina.See study design
What are the potential side effects?
Potential side effects may include typical risks associated with eye surgery such as discomfort or infection at the injection site, inflammation inside the eye, changes in intraocular pressure or cataract formation. Gene therapy-specific reactions could also occur.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in retinal thickness (as measured by OCT)
Incidence of dose limiting toxicities
Number of adverse events related to OPGx-001
+1 moreSecondary outcome measures
Change from baseline to month 12 in best corrected visual acuity (BCVA)
Change from baseline to month 12 in dark-adapted transient pupillary light reflexes (TPLR)
Change from baseline to month 12 in oculomotor control and fixation stability
+2 moreTrial Design
3Treatment groups
Experimental Treatment
Group I: Dose Group 3Experimental Treatment1 Intervention
Single, unilateral subretinal administration of a high dose of OPGx-001 to adult participants at least 18 years of age
Group II: Dose Group 2Experimental Treatment1 Intervention
Single, unilateral subretinal administration of an intermediate dose of OPGx-001 to adult participants at least 18 years of age
Group III: Dose Group 1Experimental Treatment1 Intervention
Single, unilateral subretinal administration of a low dose of OPGx-001 to adult participants at least 18 years of age
Find a Location
Who is running the clinical trial?
Opus Genetics, IncLead Sponsor
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I cannot take oral steroids for medical reasons.I haven't used any experimental drugs or devices recently and don't plan to join another study soon.I haven't had eye surgery in the last 6 months.I have undergone gene therapy before.I am 18 years old or older.I do not have eye conditions or other diseases that would prevent surgery.I am unable to do vision tests for reasons other than poor eyesight.My doctor thinks I am a good candidate for surgery.I have LCA5 gene mutations confirmed by a certified lab.I am not pregnant and willing to use effective birth control during and for a year after the study.
Research Study Groups:
This trial has the following groups:- Group 1: Dose Group 1
- Group 2: Dose Group 2
- Group 3: Dose Group 3
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many individuals have been recruited into this research endeavor?
"Indeed, the clinicaltrials.gov database illustrates that this medical trial is currently enrolling patients. Initially posted on June 15th of 2023 and having last been updated at the same date, 9 participants are required from one centre in order to proceed with the study."
Answered by AI
Are there any slots left in this trial?
"Affirmative. Data found on clinicaltrials.gov reveals that this research, which was initially announced on June 15th 2023, is actively recruiting for volunteers. Specifically, 9 participants need to be sourced from 1 medical centre."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger